Comparative effectiveness of vedolizumab and ustekinumab as induction therapy in anti-TNF refractory Crohn's disease: a multi-centre retrospective cohort study

被引：2
|
作者：
Townsend, T. [1 ]
Razanskaite, V. [2 ]
Michail, S. [1 ]
Morgan, J. [1 ]
Davies, M. [1 ]
Storey, D. [1 ]
Watters, C. [3 ]
Penman, D. [3 ]
Swaminathan, M. [4 ]
Sabine, J. [3 ]
Chapman, A. [2 ]
Vyas, A. [2 ]
Reilly, I. [4 ]
Flanagan, P. [3 ]
Bodger, K. [2 ]
Subramanian, S. [1 ]
机构：
[1] Royal Liverpool Univ Hosp, Gastroenterol, Liverpool, Merseyside, England
[2] Aintree Univ Hosp NHS Fdn Trust, Gastroenterol, Liverpool, Merseyside, England
[3] Arrowe Pk Hosp, Gastroenterol, Upton, England
[4] Countess Chester Hosp, Gastroenterol, Chester, Cheshire, England
来源：
JOURNAL OF CROHNS & COLITIS | 2019年 / 13卷
关键词：
D O I：
10.1093/ecco-jcc/jjy222.710
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P586
引用
收藏
页码：S407 / S408
页数：2
相关论文
共 50 条
  • [41] Real World Evidence Comparing Vedolizumab and Ustekinumab in Anti-TNF Experienced Patients With Crohn's Disease
    Kappelman, Michael
    Adimadhyam, Sruthi
    Hou, Laura
    Simon, Andrew L.
    Dobes, Angela
    Parlett, Lauren E.
    Haynes, Kevin
    Selvan, Mano
    Ma, Qianli
    Nair, Vinit
    Burris, Jessica L.
    Dorand, Jennifer E.
    Long, Millie
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10): : S519 - S520
  • [42] Comparative Effectiveness of Ustekinumab and Anti-TNF Agent as First-Line Biological Therapy in Luminal Crohn's Disease: A Retrospective Study From 2 Referral Centers
    Riviere, Pauline
    Kanters, Caitlyn
    Pellet, Gauthier
    Ni, Alexander
    Hupe, Marianne
    Aboulhamid, Nesrine
    Poullenot, Florian
    Bitton, Alain
    Zerbib, Frank
    Lakatos, Peter L.
    Afif, Waqqas
    Laharie, David
    Bessissow, Talat
    INFLAMMATORY BOWEL DISEASES, 2023, 29 (06) : 923 - 931
  • [43] WHICH SECOND-LINE BIOLOGIC AFTER ANTI-TNF FAILURE DURING CROHN'S DISEASE: USTEKINUMAB OR VEDOLIZUMAB, A MULTICENTRE RETROSPECTIVE STUDY
    Rayer, Cassandra
    Roblin, Xavier
    Laharie, David
    Flamant, Mathurin
    Dewitte, Marie
    Fumery, Mathurin
    Caron, Benedicte
    Viennot, Stephanie
    Pariente, Benjamin
    Laurent, Siproudhis
    Peyrin-Biroulet, Laurent
    Bouguen, Guillaume
    GASTROENTEROLOGY, 2020, 158 (06) : S958 - S958
  • [44] Which second-line biologic after anti-TNF failure during Crohn's disease: Ustekinumab or vedolizumab, a multicentre retrospective study
    Rayer, C.
    Roblin, X.
    Laharie, D.
    Caron, B.
    Flamant, M.
    Dewitte, M.
    Fumery, M.
    Viennot, S.
    Bourreille, A.
    Pariente, B.
    Siproudhis, L.
    Peyrin-Biroulet, L.
    Bouguen, G.
    JOURNAL OF CROHNS & COLITIS, 2020, 14 : S547 - S547
  • [45] The Effectiveness of Ustekinumab and Vedolizumab as Third-line Therapy in Patients with Refractory Crohn's Disease
    Macaluso, F. S.
    Grova, M.
    Saladino, M.
    Demarzo, M. G.
    Privitera, A. C.
    Giangreco, E.
    Garufi, S.
    Renna, S.
    Casa, A.
    Ventimiglia, M.
    Cappello, M.
    Fries, W.
    Orlando, A.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I359 - I359
  • [46] The Effectiveness of Ustekinumab and Vedolizumab as Third-line Therapy in Patients with Refractory Crohn's Disease
    Macaluso, F. S.
    Grova, M.
    Saladino, M.
    Demarzo, M. G.
    Privitera, A. C.
    Giangreco, E.
    Garufi, S.
    Renna, S.
    Casa, A.
    Ventimiglia, M.
    Cappello, M.
    Fries, W.
    Orlando, A.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I359 - I359
  • [47] THE EFFECTIVENESS OF USTEKINUMAB AND VEDOLIZUMAB AS THIRD-LINE THERAPY IN PATIENTS WITH REFRACTORY CROHN'S DISEASE
    Macaluso, F. S.
    Grova, M.
    Saladino, M.
    Demarzo, M. G.
    Privitera, A. C.
    Giangreco, E.
    Garufi, S.
    Renna, S.
    Casa, A.
    Ventimiglia, M.
    Cappello, M.
    Fries, W.
    Orlando, A.
    DIGESTIVE AND LIVER DISEASE, 2022, 54 : S93 - S94
  • [48] Letter: choosing between ustekinumab and vedolizumab in anti-TNF refractory Crohn's disease-the devil is in the detail. Authors' reply
    Alric, Hadrien
    Amiot, Aurelien
    Carbonnel, Franck
    Meyer, Antoine
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2020, 52 (03) : 563 - 564
  • [49] Comparative study of the effectiveness of vedolizumab versus ustekinumab after anti-TNF failure (VERSUS-CD)
    Garcia, M. J.
    Rivero, M.
    Fernandez-Clotet, A.
    de Francisco, R.
    Sicilia, B.
    Mesonero, F.
    de Castro, M. L.
    Casanova, M. J.
    Bertoletti, F.
    Garcia Alonso, F. J.
    Lopez Garcia, A.
    Julian, B.
    Calvet, X.
    Barreiro-de Acosta, M.
    Jara, L.
    Varela, P.
    Nunez, A.
    Ricart, E.
    Riestra, S.
    Arias, L.
    Rodriguez, M.
    Arranz, L.
    Pajares, R.
    Mena, R.
    Calafat, M.
    Camo, P.
    Jimenez, L.
    Ponferrada, A.
    Madrigal, R. E.
    Llao, J.
    Sese, E.
    Almela, P.
    Codesido, L.
    de la Maza, S.
    Leal, C.
    Sanchez, E.
    Pineda Marino, J. R.
    Domenech, E.
    Chaparro, M.
    Gisbert, J. P.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I121 - I123
  • [50] USTEKINUMAB IS ASSOCIATED WITH BETTER EFFECTIVENESS OUTCOMES WHEN COMPARED TO VEDOLIZUMAB IN CROHN'S DISEASE PATIENTS WITH PRIOR FAILURE TO ANTI-TNF: A COMPARATIVE EFFECTIVENESS STUDY FROM THE DUTCH ICC REGISTRY
    Biemans, Vince
    Van der Woude, Christien Janneke
    Dijkstra, Gerard
    Meulen-de Jong, Andrea V.
    Lowenberg, Mark
    de Boer, Nanne
    Oldenburg, Bas
    Srivastava, Nidhi
    Jansen, Jeroen M.
    Bodelier, Alexander
    West, Rachel
    de Vries, Annemarie C.
    Haans, Jeoffrey
    De Jong, Dirk J.
    Hoentjen, Frank
    Pierik, Marie
    GASTROENTEROLOGY, 2020, 158 (06) : S207 - S208
12345